FDA’s Office of Women’s Health

by | Mar 10, 2021 | FDA, Quality, Women Owned, Women's Health

In today’s day and age, women’s health is more important than ever. There are several international health initiatives directed at providing resources and improving the overall health of women globally. In alignment with that, the FDA also has its own established Office of Women’s Health (OWH). The OWH was established in 1994 with the main mission to serve as the principal adviser to the FDA Commissioner on “scientific, ethical, and policy issues related to women’s health”.1

A key part of the OWH’s mission is accomplished by funding research grants for 1-2 studies each year that address women’s health issues and the impact of gender differences on the safety and efficacy of drugs and medical devices. These studies also typically address certain regulatory questions when it comes to the effects of gender on FDA-regulated products. In 2020, one of the studies that the OWH funded was on the sex differences in Alzheimer’s disease. This study investigated novel technologies for the discovery of potential biomarkers and new therapies for women with the disease. Additionally, the OWH also funded a study in 2020 that looked at the sex differences in the expression of biomarkers that could diagnose early HIV-1 infections.2

On top of the groundbreaking research that the OWH funds annually, the office also works towards increasing the number of diverse women in clinical trials. It is important to include women of different ages, ethnic backgrounds, and disabilities in clinical trials to ensure the safety and efficacy of the product are consistent across all populations. The OWH’s Diverse Women in Clinical Trials Initiative also helps the industry share best practices about clinical trial design, recruitment, and subpopulation analyses.3

The OWH has also founded numerous community outreach programs such as the Mammography Awareness Initiative, Use Medicines Wisely Campaign, and the Take Time to Care Program which provides reliable health information targeted at Women’s Health. I have been honored to work with several firms that have women’s health products during my time with EMMA International. Whether it is during the clinical trial phase of these products or assisting with the regulatory submissions to get these products on the market, it is a great feeling knowing that I am playing a small part in the global initiative towards equality in the healthcare space for women. If you need help with any quality, regulatory, or compliance aspect of your product, EMMA International’s team of experts has you covered! Contact us at 248-987-4497 or email info@emmainternational.com today!


1FDA (December 2019) Office of Women’s Health retrieved on 03/07/2021 from: https://www.fda.gov/about-fda/office-commissioner/office-womens-health

2FDA (July 2020) List of OWH Research Program Awards by Funding Year retrieved on 03/07/2021 from: https://www.fda.gov/science-research/womens-health-research/list-owh-research-program-awards-funding-year

3FDA (August 2019) Women in Clinical Trials retrieved on 03/07/2021 from: https://www.fda.gov/consumers/womens-health-topics/women-clinical-trials

Madison Green

Madison Green

Director of Technical Operations - Mrs. Green serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Mrs. Green also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Mrs. Green holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

The End of the COVID-19 Public Health Emergency

The End of the COVID-19 Public Health Emergency

After over 3 years, the COVID-19 Public Health Emergency (PHE) will end on May 11, 2023, the Biden Administration announced last week.1After 3.5 years of the modified policy to allow for amore efficient path for COVID-19-related medical products to get to market, this begs the question of how it will impact the MedTech world.
Process Validation

Process Validation

All right, you have just gotten all of your paperwork together, submitted the right forms to the right people, set up your factory, hired and trained your staff; now it’s time to make the medical devices. The regulatory nonsense is over and done, right?
The Role of Management in Product Quality

The Role of Management in Product Quality

Depending on the factory, some production employees may find it surprising that management has an important role to play in a quality system.  21 CFR 820.20 mandates that “Management with executive responsibility shall establish objectives for, and commitment to, quality”.[1]  The Federal Government expects that management takes an active interest in improving the output of their company, at least in the case of medical device manufacturers.

Ready to learn more about working with us?

Pin It on Pinterest

Share This